This article is more than 5 years old. Information may no longer be current.

Subconjunctival anti-VEGF shows promise in the treatment of corneal neovascularization

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ROME — The use of subconjunctival bevacizumab may represent a promising method in the treatment of corneal neovascularization, according to a study at Charles University in Prague, Czech Republic.

At the winter meeting of the European Society of Cataract and Refractive Surgeons, Pavel Studeny, MD, presented the results of 17 eyes of 17 consecutive adult patients with corneal neovascularization who received subconjunctival injection of Avastin (bevacizumab, Genentech) in the dose of 0.75 mg per 0.03 mL. The mean age of the patients was 59 years (range, 25 years to 81 years).

"A considerable reduction of corneal neovascularization was obtained. No intraoperative complication occurred, and at 6 months, no side effects or complications have been reported by the patients," he said.